AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
24/7 Wall St. on MSN6d
AbbVie Just Paid Investors: Here’s How Much They ReceivedAbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.
AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...
Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
The stock's fall snapped a two-day winning streak.
AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets ...
GlobalData on MSN7d
AbbVie and Xilio to collaborate on antibody-based immunotherapiesAbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback